Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
6.33
+0.26 (4.28%)
At close: May 4, 2026, 4:00 PM EDT
6.33
0.00 (0.00%)
After-hours: May 4, 2026, 4:10 PM EDT
Minerva Neurosciences Employees
Minerva Neurosciences had 7 employees as of December 31, 2025. The number of employees decreased by 1 or -12.50% compared to the previous year.
Employees
7
Change (1Y)
-1
Growth (1Y)
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$41,917,597
Market Cap
277.52M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7 | -1 | -12.50% |
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | 0 | - |
| Dec 31, 2022 | 9 | 0 | - |
| Dec 31, 2021 | 9 | -2 | -18.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| LENZ Therapeutics | 152 |
| Coherus Oncology | 147 |
| Adagene | 128 |
| Foghorn Therapeutics | 106 |
| Artiva Biotherapeutics | 104 |
| Alector | 103 |
| Compugen | 75 |
NERV News
- 4 weeks ago - Minerva Announces Leadership Transition - GlobeNewsWire
- 4 weeks ago - Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia - GlobeNewsWire
- 5 weeks ago - Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 - GlobeNewsWire
- 6 weeks ago - Minerva Neurosciences Transcript: Stifel 2026 Virtual CNS Forum - Transcripts
- 7 weeks ago - Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - GlobeNewsWire
- 7 weeks ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates - GlobeNewsWire
- 7 weeks ago - Minerva Neurosciences Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 2 months ago - Minerva Neurosciences to Participate in The Citizens Life Sciences Conference - GlobeNewsWire